Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Kreutzer, TC; Wolf, A; Dirisamer, M; Strauss, RW; Foerster, P; Feltgen, N; Pielen, A; Hattenbach, LO; Kampik, A; Priglinger, SG.
Intravitreal ranibizumab versus isovolemic hemodilution in the treatment of macular edema secondary to central retinal vein occlusion: twelve-month results of a prospective, randomized, multicenter trial.
Ophthalmologica. 2015; 233(1):8-17
Doi: 10.1159/000369566
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Strauß Rupert
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- This is a prospective, randomized, multicenter, investigator-initiated trial to evaluate the 12-month effectiveness of isovolemic hemodilution (IH) with prompt versus deferred intravitreal injections (IVI) of ranibizumab 0.5 mg for the treatment of macular edema secondary to early central retinal vein occlusion (CRVO). Eyes with macular edema due to CRVO having occurred not more than 8 weeks previously received either monthly ranibizumab IVI in combination with IH (group I, n = 28) or IH alone (group II, n = 30). From month 2 to 12, the patients in both groups could be treated with monthly intravitreal ranibizumab. The main outcome variables were gain of visual acuity and the course of central retinal thickness as measured with optical coherence tomography. At 12 months, eyes in group I on average gained +28.1 (±19.3) letters compared to +25.2 (±20.9) letters in group II (p = 0.326). This result was achieved with significantly fewer injections in group II. Additionally, 30% of the eyes in group II did not need ranibizumab IVI during the 12 months of the trial. Ranibizumab IVI in addition to IH proved to be highly effective in increasing visual acuity and reducing macular edema secondary to CRVO. Initial IH in early CRVO may be a first treatment option in patients anxious about IVI. © 2014 S. Karger AG, Basel.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Aged -
- Aged, 80 and over -
- Angiogenesis Inhibitors - therapeutic use
- Antibodies, Monoclonal, Humanized - therapeutic use
- Blood Viscosity -
- Female -
- Fluorescein Angiography -
- Hemodilution - methods
- Humans -
- Intravitreal Injections -
- Macular Edema - drug therapy
- Macular Edema - etiology
- Macular Edema - therapy
- Male -
- Middle Aged -
- Prospective Studies -
- Ranibizumab -
- Retinal Vein Occlusion - complications
- Tomography, Optical Coherence -
- Vascular Endothelial Growth Factor A - antagonists & inhibitors
- Visual Acuity - physiology
- Find related publications in this database (Keywords)
- Central retinal vein occlusion
- Hemodilution
- Randomized trial
- Ranibizumab
- Vascular endothelial growth factor